TRAb和T淋巴细胞亚群联合检测对预测Graves病复发的临床意义

采用酶联免疫法和单克隆抗体法测定４２例Ｇｒａｖｅｓ病人，在用丙基硫氧嘧啶（ＰＴＵ）治疗过程中ＴＳＨ受体抗体（ＴＲＡｂ）和外周血Ｔ淋巴细胞亚群的变化，并对病人停药后随诊一年的结果表明ＰＴＵ治疗１８个月后，ＴＲＡｂ持续高水平和Ｔ淋巴细胞未恢复到正常者易复发。     

~(131)I治疗Graves’病后发生甲低与TGA,TMA及TRAb的关系

目的 :从甲状腺自身免疫方面探讨1 3 1 I治疗甲亢的效果及甲低发生的因素。方法 :选择1 3 1 I治疗的88例Graves’病甲亢患者随访 3年 ,分为第 1组 (TGA、TMA、TRAb均阳性 )和第二组 (TGA、TMA阴性 ,TRAb阳性 )。采用x2 分析自身抗体水平与甲低发生的关系。结果 :1组甲低发生率为 31 4 % ,2组为 3 8% ,1组明显高于 2组 ,差异有显著性。结论 :TGA、TMA和TRAb水平与确定1 3 1 I剂量及甲低的发生关系密切。认为TGA、TMA水平高的患者应酌情减少1 3 1 I用量     

131I治疗Graves病对血清TRAb、TGAb和TPOAb的影响及其临床意义

目的 临床观察131I治疗Graves病的疗效,比较治疗前后TRAb、TGAb和TPOAb的变化情况,并分析其临床意义.方法 选取2011年6月-2014年4月于该院就诊的经131I治疗的Graves病患者40例,进行治疗后临床疗效的评价,于治疗前4周内及治疗后3、6、12、18个月抽取空腹静脉血,分离出血清,测定TRAb、TGAb、TPOAb等.同时随机选取我院体检中心同期体检合格的健康人40例作为对照组,测定上述指标.结果 治疗12个月后,47.5％的患者甲状腺功能恢复正常,30.0％的患者发生甲低,而仍有22.5％的患者处于甲亢状态,临床总治愈率为77.5％.抗体阳性组的治愈率为88.5％,早发甲低率为38.5％,抗体阴性组分别为57.1％、14.2％,二组间临床治愈率差异有统计学意义(x2=5.119,P=0.024),而早发甲低率差异无统计学意义(x2=2.553,P=0.112).观察组在治疗前及各治疗时间段内三种抗体的浓度均明显大于对照组(P＜0.05);观察组内,治疗3个月后、6个月后三抗体的水平较治疗前明显升高(P＜0.05),治疗18个月后则明显低于治疗前水平(P＜0.05).结论 131I治疗Graves甲亢具有良好的疗效,TRAb、TGAb、TPOAb与Graves病密切相关,治疗前检测甲状腺自身抗体对采取131I治疗的患者有重要的指导意义.     

~(131)碘治疗Grave′s病后检测血清TRAb的临床价值

目的:分析Grave′s病患者131碘治疗后的血清TRAb变化,探讨TRAb在131碘治疗甲亢中的应用价值。方法:采用放射受体分析法检测了101例131碘治疗的Grave′s病患者血清TRAb,根据131碘治疗后对血清TRAb变化进行对比分析。结果:甲亢持续组TRAb升高阳性率明显高于甲亢治愈组,两者之间差异有显著性(P<0.05)。而在131碘治疗后TRAb的变化与甲亢严重无关(P>0.05)。结论:TRAb检测在Grav′s病131碘治疗中具有重要指导作用。     

Graves病与Graves眼病的FT3、FT4、STSH、TGAb、TMAb、TRAb检测及临床意义

目的 探讨FT3、FT4、STSH、TGAb、TMAb、TRAb与Graves眼病(GO)的关系,了解各指标在GO患者发病中的作用.方法 采用放射免疫分析法检测64例Graves病(GD)患者及121例GO患者血清FT3、FT4、STSH、TGAb、TMAb、TRAb值,并对两组各指标的检测值及TRAb阳性检出率进行比较.结果 两组患者血清FT3、FT4、STSH、TGAb、TMAb活性差别无统计学意义(P＞0.05);GO组及GD组TRAb活性分别为(27.54±5.62)u/l和(11.48±9.55)u/l,GO组明显高于GD组(P＜0.05);GO组及GD组阳性检出率分别为72.73%和51.56%,GO组显著高于GD组(P＜0.005).结论 两组患者甲状腺的功能状态相同;TRAb在GO的诊断中具有重要意义;推测GD患者血清TRAb显著增高是合并或随病程延长可能合并GO的重要标志.     

Increased sensitivity of a new assay for anti-thyroglobulin antibody detection in patients with autoimmune thyroid disease

OBJECTIVES: To verify the cut-off values and to determine the clinical sensitivity of antithyroglobulin (TgAb) determinations using our routine RIA and the new electrochemiluminescent Elecsys assay. DESIGN AND METHODS: We used the DYNOtest anti-Tgn manual RIA from BRAHMS and the new automated Elecsys electrochemiluminescent immunoassay from Roche Diagnostics. We analyzed 452 sera from the following subjects: 193 euthyroid controls, 163 with treated and untreated autoimmune thyroid diseases (AITD) (108 Graves' disease and 55 thyroiditis), 50 with differentiated thyroid carcinoma, 13 with nonautoimmune thyroid disease and 33 with type 1 diabetes mellitus. RESULTS: As expected, using the proposed thresholds (BRAHMS 60 kIU/L, Elecsys 115 kIU/L) approximately 6% of the control subjects were positive for TgAb with both methods. In AITD patients, the sensitivity of TgAb determination was significantly higher with the Elecsys assay (51.5%) than with the BRAHMS assay (39.3%). This difference was not observed in the other patient groups. CONCLUSION: The Elecsys assay can be preferred not only because it is automated and rapid, but also because of its better clinical performance in AITD patients.     

正丁醇法制备大鼠脂肪组织细胞膜TSHR

目的:利用正丁醇对大鼠脂肪组织细胞膜上的促甲状腺素受体(TSHR)进行提纯,以获得膜受体的均一水溶性溶液。方法:使用差速离心法获得大鼠含TSHR脂肪组织细胞膜碎片后,用正丁醇进一步提纯;采用SDS-PAGE和ELISA法鉴定所得蛋白完整性、生物学活性,并用BCA法测定相关蛋白含量。结果:正丁醇提纯的大鼠TSHR结构完整;经正丁醇提纯后的TSHR包被酶标孔孔间测定值变异系数较未经正丁醇提取组以及阳性对照组低。结论:经正丁醇提纯后的大鼠TSHR可以满足临床ELISA法检测Graves病患者血清TRAb的要求,同时可以降低酶标孔间测定值的误差。     

Salivary cortisol on ROCHE Elecsys immunoassay system: pilot biological variation studies

OBJECTIVES: Salivary analysis is a noninvasive alternative that may be more acceptable to patients, especially children. As such, it has the potential for incorporation into comprehensive, dynamic investigations of metabolic dysfunctions - a significant advancement over a single time point serum analysis. In this study, we wanted to determine if the serum cortisol assay on our routine immunoassay analyzer could reliably measure salivary cortisol concentrations. Because of potential fluctuations in salivary concentrations, we included a biologic variation study as a main facet of our preliminary method evaluation. DESIGN AND METHODS: Twenty-eight healthy individuals (12 males, 16 females) volunteered to provide 5 nonconsecutive first morning saliva samples over a two-week period. Samples were stored frozen at home until the completion of the study. Following thawing and centrifugation, cortisol was measured in batch mode for each set of participant samples on the ROCHE Elecsys. Biologic variation was determined following removal of outliers. A method comparison was performed with the DPC Coat-A-Count Cortisol assay following the recommended modifications for salivary analysis, and with the Salimetrics HS-Cortisol two-site monoclonal assay optimized for salivary cortisol. RESULTS: Mean salivary cortisol concentration was 20.4 nmol/L. Analytical variation (CV(A) = 3.8%), within-subject variation (CV(I) = 6.3%), between-subject variation (CV(G) = 20.5%), index of individuality (II = 0.36) and reference change value (RCV = 20.4%) were determined. A negative 40% proportional bias was observed on the Elecsys compared to the two methods that have already been optimized for salivary analysis.CONCLUSIONS: This study demonstrated that salivary cortisol can be reliably measured on a routine automated immunoassay analyzer such as the ROCHE Elecsys. This particular assay needs to be optimized at the low end of the standard curve for routine use with salivary samples. Based on the relatively small intra-individual variation and low index of individuality, reference change values are preferable to the use of population reference intervals for this assay.     

甲亢患者手术前后TSH受容体抗体的变化及临床意义

目的探讨作为甲状腺机能亢进症（甲亢）主要发病因子的ＴＳＨ受容体抗体（ＴＲＡｂ）在甲状腺切除手术前、后的变化及其临床意义。方法对９１例甲亢患者进行ＴＲＡｂ追踪测定，并根据术前ＴＲＡｂ值将其分为正常组，弱阳性组，中度阳性组和强阳性组，分别讨论其变化特点。结果术前ＴＲＡｂ阳性例术后１２～１８月间大部分转为正常或呈明显下降趋势；而甲状腺机能则全部转为正常或潜在性低下及低下状态。阳性组ＴＲＡｂ术后恢复正常的例数所占比率分别为２５／２７、１０／１７和２／８。结论外科手术治疗甲亢可以使ＴＲＡｂ转为阴性，因此，不但在临床上而且针对病因治疗也都有效，但目前尚无法治愈所有甲亢患者。